Sanofi's Dupixent Drug Review Date Extended by Three Months in the U.S.
By Ian Walker
French pharmaceutical company Sanofi said that the priority review date in the U.S. for its chronic obstructive pulmonary disease treatment, Dupixent, but stressed that there weren't any concerns over the drug.
The U.S. Food and Drug Administration asked for more information from recent trials of Dupixent, and said that the extra data constitutes a major amendment to the supplemental biologics license application. It has therefore extended the date for its review to Sept. 27.
"Sanofi and Regeneron are confident that the additional analyses strongly support the approval of Dupixent in COPD with evidence of type 2 inflammation, and are committed to working with the FDA to bring Dupixent to patients living with uncontrolled COPD as quickly as possible," the companies said.
Sanofi and Regeneron are jointly developing Dupixent under a global collaboration agreement.
Separately, the European Medicines Agency's Committee for Medicinal Products for Human Use recommended Dupixent for European Union approval.
The EU is expected to announce a final decision on the Dupixent application in the coming months.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
May 31, 2024 01:49 ET (05:49 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks